 MONTREAL and CHARLOTTE, N.C. , Oct. 3, 2019 CNW -- Milestone Pharmaceuticals Inc. MIST, a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Companys open-label, global safety study of etripamil, the Companys novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia PSVT. Commencement of enrollment in NODE-303 marks an important step forward for our Phase 3 program of etripamil in PSVT, where current standards of care are restricted to the burdensome and costly acute care setting, said Joseph Oliveto , President and Chief Executive Officer of Milestone Pharmaceuticals. 